Paladin Wealth LLC Sells 15,224 Shares of Pfizer Inc. $PFE

Key Points

• Paladin Wealth LLC reduced its holdings in Pfizer Inc. by 56.2% in Q2, now owning 11,864 shares valued at $288,000 after selling 15,224 shares.
• Despite recent fluctuations, Wall Street analysts have mixed views on Pfizer's stock, with a consensus rating of "Hold" and an average target price of $28.12.
• Pfizer recently reported earnings per share of $0.78 for Q2, exceeding estimates, along with a quarterly dividend of $0.43, providing a yield of 7.2%.

Paladin Wealth LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 56.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,864 shares of the biopharmaceutical company's stock after selling 15,224 shares during the quarter. Paladin Wealth LLC's holdings in Pfizer were worth $288,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of PFE. Gould Capital LLC grew its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the 1st quarter valued at about $27,000. North Capital Inc. purchased a new stake in Pfizer during the 1st quarter valued at about $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer during the 1st quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer during the 4th quarter valued at about $30,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PFE. Berenberg Bank reduced their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. HSBC reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Finally, Jefferies Financial Group boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Stock Performance

Shares of NYSE PFE opened at $23.91 on Monday. The firm has a 50 day moving average of $24.79 and a 200 day moving average of $24.27. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $135.94 billion, a price-to-earnings ratio of 12.72, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.